Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission

Mine Harada; Koichi Akashi; Shin Hayashi; Tetsuya Eto; Yasushi Takamatsu; Takanori Teshima; Yuichi Hirota; Shuichi Taniguchi; Koji Nagafuji; Shinichi Mizuno; Hisashi Gondo; Yoshiyuki Niho

Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission

Mine Harada, Koichi Akashi, Shin Hayashi, Tetsuya Eto, Yasushi Takamatsu, Takanori Teshima, Yuichi Hirota, Shuichi Taniguchi, Koji Nagafuji, Shinichi Mizuno, Hisashi Gondo, Yoshiyuki Niho

Research output: Contribution to journal › Article

11 Citations (Scopus)

Abstract

We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C); and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high- dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy: At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.

Original language	English
Pages (from-to)	297-301
Number of pages	5
Journal	International Journal of Hematology
Volume	66
Issue number	3
Publication status	Published - Oct 1 1997
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

Fingerprint Dive into the research topics of 'Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission'. Together they form a unique fingerprint.

Cite this

Harada, M., Akashi, K., Hayashi, S., Eto, T., Takamatsu, Y., Teshima, T., Hirota, Y., Taniguchi, S., Nagafuji, K., Mizuno, S., Gondo, H., & Niho, Y. (1997). Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. International Journal of Hematology, 66(3), 297-301.

Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. / Harada, Mine; Akashi, Koichi; Hayashi, Shin; Eto, Tetsuya; Takamatsu, Yasushi; Teshima, Takanori; Hirota, Yuichi; Taniguchi, Shuichi; Nagafuji, Koji; Mizuno, Shinichi; Gondo, Hisashi; Niho, Yoshiyuki.

In: International Journal of Hematology, Vol. 66, No. 3, 01.10.1997, p. 297-301.

Research output: Contribution to journal › Article

Harada, M, Akashi, K, Hayashi, S, Eto, T, Takamatsu, Y, Teshima, T, Hirota, Y, Taniguchi, S, Nagafuji, K, Mizuno, S, Gondo, H & Niho, Y 1997, 'Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission', International Journal of Hematology, vol. 66, no. 3, pp. 297-301.

Harada, Mine ; Akashi, Koichi ; Hayashi, Shin ; Eto, Tetsuya ; Takamatsu, Yasushi ; Teshima, Takanori ; Hirota, Yuichi ; Taniguchi, Shuichi ; Nagafuji, Koji ; Mizuno, Shinichi ; Gondo, Hisashi ; Niho, Yoshiyuki. / Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. In: International Journal of Hematology. 1997 ; Vol. 66, No. 3. pp. 297-301.

@article{302f8fa57abe4c58be8292e6005f9cc2,

title = "Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission",

abstract = "We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C); and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high- dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy: At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.",

author = "Mine Harada and Koichi Akashi and Shin Hayashi and Tetsuya Eto and Yasushi Takamatsu and Takanori Teshima and Yuichi Hirota and Shuichi Taniguchi and Koji Nagafuji and Shinichi Mizuno and Hisashi Gondo and Yoshiyuki Niho",

year = "1997",

month = oct,

day = "1",

language = "English",

volume = "66",

pages = "297--301",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission

AU - Harada, Mine

AU - Akashi, Koichi

AU - Hayashi, Shin

AU - Eto, Tetsuya

AU - Takamatsu, Yasushi

AU - Teshima, Takanori

AU - Hirota, Yuichi

AU - Taniguchi, Shuichi

AU - Nagafuji, Koji

AU - Mizuno, Shinichi

AU - Gondo, Hisashi

AU - Niho, Yoshiyuki

PY - 1997/10/1

Y1 - 1997/10/1

N2 - We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C); and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high- dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy: At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.

AB - We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C); and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high- dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy: At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.

UR - http://www.scopus.com/inward/record.url?scp=0031257473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031257473&partnerID=8YFLogxK

M3 - Article

C2 - 9401275

AN - SCOPUS:0031257473

VL - 66

SP - 297

EP - 301

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -